A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies

Trial Profile

A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd; Pfizer
  • Most Recent Events

    • 09 Apr 2018 Status changed from recruiting to completed.
    • 03 Apr 2018 This trial was completed in Germany (End date: 2018-03-20), according to European Clinical Trials Database.
    • 23 Feb 2018 This trial was completed in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top